January 1, 2019
The National Institute for Innovative Manufacturing of Biopharmaceuticals (NIIMBL) has awarded the consortium comprised of Artemis Biosystems, Johns Hopkins University, MassBiologics, Rensselaer Polytechnic Institute, Repligen and Unum Therapeutics a grant entitled "Improved Lentiviral Vector Biomanufacturing for Cell and Gene Therapy Applications”. The consortium will use VHU technology supplied by Artemis Biosystems to achieve its goal of developing a perfusion-based method of highly efficient, large scale manufacturing of lentiviral vectors. See: https://niimbl.force.com/s/pc10-012
February 20, 2018
Bluebird Bio (www.bluebirdbio.com), a leading gene therapy company based in Cambridge (MA), is working with Artemis Biosystems to evaluate its VHU filtration technologies as part of its ongoing viral vector process development efforts.